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Abstract
Background Metronomic chemotherapy has shown
promising activity against solid tumors and is believed to
act in an antiangiogenic manner. The current study
describes and quantifies the therapeutic efficacy, and mode
of activity, of metronomic gemcitabine and a dedicated
antiangiogenic agent (DC101) in patient-derived xeno-
grafts of pancreatic cancer.
Methods Two primary human pancreatic cancer xeno-
graft lines were dosed metronomically with gemcitabine or
DC101 weekly. Changes in tumor growth, vascular func-
tion, and metabolism over time were measured with mag-
netic resonance imaging, positron emission tomography,
and immunofluorescence microscopy to determine the anti-
tumor effects of the respective treatments.
Results Tumors treated with metronomic gemcitabine
were 10-fold smaller than those in the control and DC101
groups. Metronomic gemcitabine, but not DC101, reduced
the tumors’ avidity for glucose, proliferation, and apoptosis.
Metronomic gemcitabine-treated tumors had higher perfu-
sion rates and uniformly distributed blood flow within the
tumor, whereas perfusion rates in DC101-treated tumors
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were lower and confined to the periphery. DC101 treatment
reduced the tumor’s vascular density, but did not change
their function. In contrast, metronomic gemcitabine
increased vessel density, improved tumor perfusion tran-
siently, and decreased hypoxia.
Conclusion The aggregate data suggest that metronomic
gemcitabine treatment affects both tumor vasculature and
tumor cells continuously, and the overall effect is to sig-
nificantly slow tumor growth. The observed increase in
tumor perfusion induced by metronomic gemcitabine may
be used as a therapeutic window for the administration of a
second drug or radiation therapy. Non-invasive imaging
could be used to detect early changes in tumor physiology
before reductions in tumor volume were evident.
Keywords Metronomic chemotherapy  Anti-
angiogenesis  Tumor physiology  Gemcitabine 




mSDF-1a Mouse stromal cell-derived factor-1a
DCE-MRI Dynamic contrast-enhanced magnetic
resonance imaging
FDG-PET 18F-fluorodeoxyglucose positron emission
tomography
Gd-DTPA Gadolinium diethylenetriamine penta-acetic
acid
hPlGF Human placental growth factor
hTSP-1 Human thrombospondin-1
Met-Gem Metronomic gemcitabine
mPDGF-BB Mouse platelet-derived growth factor-BB
MTD Maximum tolerated dose
TUNEL TdT-mediated nick end labeling
Veh-ctrl Vehicle control
VEGF Vascular endothelial growth factor
VEGFR-2 VEGF receptor 2
Background
The prognosis for pancreatic adenocarcinoma remains dire,
with a 5-year survival rate of\5 % [1]. The clinical
response to gemcitabine is significant, but its effect on
overall survival is modest [2]. In addition, gemcitabine’s
toxic side effects can be dose limiting and some pancreatic
tumors are inherently resistant to the drug. At present,
conventional chemotherapy for pancreatic cancer consists
of maximum tolerated doses (MTD) of gemcitabine, in
which the patient is given the highest possible drug dose
that does not cause life-threatening side effects. The
inherently toxic nature of MTD treatment requires drug-
free breaks to allow the patient to recover from systemic
drug toxicities before resuming the treatment. Unfortu-
nately, the tumor often reestablishes itself during the drug-
free breaks, and sometimes with acquired resistance to
gemcitabine, that renders subsequent cycles of treatment
ineffective. More effective strategies for treating and con-
trolling pancreatic cancer are thus needed.
An alternate treatment regimen for pancreatic cancer
under investigation is metronomic chemotherapy where
low doses of a cytotoxic drug are administered fre-
quently without prolonged drug-free breaks [8]. Drug
doses lower than MTD, even if given more frequently
and without rest breaks, are tolerated better by patients
and cause fewer side effects. Interestingly, studies also
indicate that drug resistant tumors can still respond to
metronomic dosing of the same drug [3, 4], implying
that direct cytotoxic kill of cancer cells is not the only
mechanism of tumor control. Cytotoxic agents also target
proliferating endothelial cells in the tumor [5], and it is
not unreasonable that metronomic chemotherapy exerts
non-specific effects on tumor vasculature that limits the
supply of oxygen and nutrients and subsequently
impedes tumor growth [6–8]. Moreover, the lack of
treatment breaks in metronomic chemotherapy also
means that the continuous presence of drug prevents
damaged vasculature from recovering [3]. The effects of
metronomic chemotherapy on tumor vasculature are lar-
gely unknown except for a handful of studies where
increased vessel perfusion was observed [9–11].
We now report here the different effects that metro-
nomic gemcitabine and DC101 treatment have on two
patient derived pancreatic tumor lines grown orthotopically
in mice. Our data show that metronomic therapy with
gemcitabine not only improves the tumor’s vascular func-
tion transiently, but also significantly retards cell prolifer-
ation and metabolism in primary human pancreatic cancer
xenografts. In contrast, DC101, a monoclonal antibody that
targets mouse vascular endothelial growth factor receptor-2
(VEGFR-2) decreases vascular density as expected but had
no effect on tumor growth in the same models. The
molecular and in situ physiological data reported here
provide more insight on the activity of metronomic gem-
citabine in primary pancreatic tumors. The information
garnered suggests that the activity of Met-Gem treatment is
not only cytotoxic, but also affects tumor vasculature
5 Pathology and Laboratory Medicine, University of British
Columbia, Vancouver, BC, Canada
6 Department of Surgery, Faculty of Medicine, University of
British Columbia, Vancouver, BC, Canada
7 The Department of Radiation Oncology, Princess Margaret
Cancer Centre, 5th Floor, 610 University Avenue, Toronto,
ON M5G 2M9, Canada
230 Angiogenesis (2016) 19:229–244
123
effects as well. The data further suggest a role for non-
invasive imaging technologies in monitoring changes in the
tumor microenvironment, which could be used to guide the
development of more effective therapies and dosing
parameters specifically for pancreatic cancer.
Methods
Orthotopic primary pancreatic cancer xenografts
Fresh pancreatic ductal adenocarcinoma (PDAC) tissues
were obtained from consented patients undergoing Whip-
ple resection at Vancouver General Hospital in 2006–2008.
Resected, non-diagnostic specimens were collected as
previously described [9, 12]. Briefly, viable tumor tissues
were implanted subcutaneously into male C.B-17 SCID
mice (Taconic, Germantown, NY, USA). When tumor
volumes reached 600–800 mm3, the subcutaneous tumors
were excised, cut into small pieces, and surgically
implanted on the pancreas of additional mice. Two primary
pancreatic ductal adenocarcinoma xenograft lines, PaCa8
and PaCa13, established from two patients were used in
this study. All animal studies were done in accordance with
the guidelines from the Canadian Council for Animal Care
and approved by the University of British Columbia’s
animal care committee.
Treatments and in vivo imaging time points
Gemcitabine hydrochloride (Gemzar; Eli Lilly Canada
Inc., Toronto, ON, Canada) was obtained from the British
Columbia Cancer Agency (BCCA) pharmacy. Mouse
monoclonal VEGFR-2 antibody, DC101, was provided by
Imclone Systems (New York, NY, USA) via a materials
transfer agreement. When the orthotopic primary xeno-
grafts reached a palpable size of 200–400 mm3, tumor-
bearing mice were randomly assigned to three groups
(n = 8/group) and treated with vehicle control (Veh-ctrl;
0.9 % saline, i.p.), DC101 (800 lg, q3d, i.p.), or metro-
nomic gemcitabine (Met-Gem; 30 mg/kg, q3d, i.p.).
Gemcitabine doses were chosen to emulate typical serum
concentrations in the clinic as reported previously [9], and
DC101 doses were based on previous studies that showed
efficacy [13, 14]. On days 3, 7, and 21 following initiation
of treatment, mice from each group were scanned with
dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) or 18F-fluorodeoxyglucose positron emission
tomography (FDG-PET). Once imaging procedures were
complete, mice were euthanized and tumors harvested for




At each time point, tumor-bearing mice were injected with
FDG (18F-radiolabeled deoxyglucose; 100 ± 5 lCi;
BCCA) via the lateral tail vein. One hour after injection,
the mice were anesthetized with isoflurane and placed on
the scanning platform. The Inveon multi-modality small
animal PET-CT scanner (Siemens, Knoxville, TN, USA)
was used for imaging studies. PET data were collected for
15 min in list mode and subsequently histogrammed into a
single frame. Images were reconstructed in three dimen-
sions using OSEM-MAP3D algorithms following CT-
based attenuation scans to correct for the animal’s body
mass. Three-dimensional regions of interest were placed on
parts of the tumor that were actively taking up FDG in the
reconstructed animal images to quantify FDG activity
present per volume of tumor tissue. FDG-PET imaging is
based on detecting the uptake of FDG by cancer cells. The
avidity of the cells for FDG, and by extension glucose, is a
gauge of the tumor’s proliferative ability and viability [15].
Generally, the more FDG is taken up by a tumor, the more
viable and proliferative the tumor is. In the clinic, FDG-
PET images are used to stage tumors and diagnose meta-
static disease [15, 16]. CT images, based on tissue densities
and injected contrast agents, provide information on the
physical volume of the tumor. The FDG signal is used to
corroborate the CT image of the tumor. Changes in the
FDG signal occur more rapidly than changes in tumor
volume, so this information can also be used to infer early
response to a treatment—i.e., if the FDG signal is reduced
by a treatment (compared to a baseline scan before treat-
ment), it indicates that the cells are less viable and prolif-
erative. We have used PET data reported here in a similar
fashion to provide additional information on the effects of
metronomic gemcitabine and DC101 on the viability and
proliferative ability of the tumor before and after treatment.
Immunofluorescence staining, microscopy,
and image analysis
Following DCE-MRI and FDG-PET, all tumor-bearing
mice were injected with the hypoxia marker EF5 (30 mg/
kg, i.v.; Dr. Cameron Koch, University of Pennsylvania,
PA, USA) and the perfusion marker Hoechst 33342
(40 mg/kg, i.v.; Sigma-Aldrich, Oakville, ON, Canada) at
3 h and 5 min, respectively, before euthanasia and imme-
diate tumor excision. Perpendicular tumor diameters were
measured with a caliper, and tumor volumes were calcu-
lated (p/6 9 a 9 b2, where ‘a’ is the longest dimension of
the tumor, and ‘b’ is the width). Tumors were preserved in
OCT (Sakura Finetek, Torrance, CA, USA) and snap-
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frozen in liquid nitrogen vapor. A known value of 10-lm
cryosections were cut from each tumor, air-dried, and
imaged first for native Hoechst 33362 fluorescence as an
indicator of tumor tissue perfusion [17]. Subsequently, the
cryosections were fixed in 50 % (v/v) acetone/methanol
and blocked in a buffer containing 1 % BSA, 1 % goat
serum, 1 % donkey serum, and 0.1 % Tween-20.
Endothelial cells were stained with a CD31/PECAM-1
primary antibody (1:1000; BD PharMingen, San Diego,
CA, USA) followed by an Alexa 647-conjugated secondary
antibody (1:20,000; Invitrogen, Burlington, ON, Canada).
Reduced EF5 adducts in viable hypoxic cells were stained
using a Cy3-conjugated monoclonal antibody to ELK3-51
(1:400; Dr. C. Koch). To visualize proliferating cells,
cryosections were stained with a Ki67 (1:100; Invitrogen)
primary antibody followed by an Alexa 488 conjugated
secondary antibody (1:200; Invitrogen). The in situ Cell
Death Detection Kit (Roche Indianapolis, IN, USA), which
involves TdT-mediated dUTP nick end labeling (TUNEL)
reaction, was used to evaluate cell apoptosis. Finally,
cryosections were counterstained with Hoechst 33362
(10 lg/mL) and mounted. Fluorescent images of whole
tumor sections were captured (910 objective) using a
microscope system (Leica Microsystems Inc., Richmond
Hill, ON, Canada) equipped with a cooled 350FX mono-
chrome CCD camera, an automated scanning stage
(DM6000B), and Surveyor software (Objective Imaging
Kansasville, WI, USA). All parameters stained on the same
cryosection were imaged separately and then overlaid and
aligned. With NIH ImageJ (http://rsb.info.nih.gov/ij/)
software and user-supplied algorithms, images were crop-
ped to tumor tissue boundaries with necrosis and artifacts
removed before quantification. The extent of hypoxia,
proliferation, and apoptosis was represented by the per-
centage of EF5?, Ki67?, and TUNEL? pixels, respec-
tively, of the total number of viable tumor tissue pixels.
The percentage of perfused vessels was reported as the
percentage of CD31 ? Hoechst ? pixels divided by the
total number of CD31 ? pixels. To measure microvessel
density, all image pixels were sorted to determine their
distance to the nearest CD31 ? pixel, and the average of
distances to the nearest vessel (i.e., CD31 ? object) was
calculated. A short average distance to the nearest vessel
indicates high microvessel density [9, 18]. The degree of
necrosis present in the tumors was calculated as a per-
centage of necrotic pixels divided by total tumor tissue
pixels; necrotic areas were identified based on side-by-side
comparisons with H&E images of the section.
Dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI)
A 7.0 Tesla MR scanner (Bruker, Ettlingen, Germany),
with a quadrature birdcage coil for transmission and a
1.7 9 1.4 cm rectangular surface coil for reception, was
used for DCE-MRI studies. At each time point, tumor-
bearing mice were anesthetized with isoflurane (Baxter
Corporation, Mississauga, ON, Canada) and given an i.v.
bolus injection of 0.3 mmol/kg of the MR contrast agent
gadodiamide (OmniscanTM; Nycomed, Oslo, Norway). 3D-
FLASH was used to acquire the data for estimating the
concentration of the contrast agent (FOV = 3.84 9
21.6 9 2.4 cm; voxel size = 0.3 9 0.3 9 1 mm): three
scans with different flip angles were used to calculate
in vivo flip angle maps [19] in order to correct the T1
estimates (anom = 145, 180, 215; TE/TR = 3.5/460 ms,
Veh-Ctrl
(n = 8)
Day 3 Day 7 Day 21
DC101
(n = 8)
Day 3 Day 7 Day 21
Met-Gem
(n = 8)
Day 3 Day 7 Day 21
DCE-MRI and 18F-FDG-PET
(n = 4)                    (n = 4)
Immunostaining of tumor cryosections and 
determination of tumor levels of soluble factors
Scheme 1 Experimental design. PaCa8 or PaCa13 xenografts were
implanted into 24 mice each. When tumors were 200–400 mm3, mice
were randomized into one of three treatment groups: vehicle (Veh-
Ctrl), anti-VEGFR-2 antibody (DC101), or metronomic gemcitabine
(Met-Gem). On days 3, 7 and 21 after treatment started, animals were
imaged with DCE-MRI or FDG-PET. Animals were euthanized
immediately after imaging, and the tumors harvested for further
analysis
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2 9 zero-filling for 0.3 9 0.3 9 1 mm voxel); a three-
scan variable flip angle method was used to calculate native
T1 in the tumor [20] (anom = 10, 20, 50; TE/TR = 2.7/
144 ms); and a rapid T1-weighted scan series (TE/
TR = 2.7/9 ms, anom = 25, 15.6 s per scan) was per-
formed before and after bolus injection of the contrast
agent (20 pre-contrast scans, 150 post-contrast scans) to
observe the initial uptake and subsequent washout in the
tumor. Concentration was derived assuming linearity
between contrast concentration and T1 according to the
equations described by Schabel and Parker [21]. The
gadodiamide concentration–time curve for each pixel was
fitted to the extended Kety model [22, 23] which describes
the pharmacokinetics of the contrast agent using three
parameters: Ktrans—volume transfer constant between
vascular space and extravascular extracellular space; ve—
fractional volume of extravascular extracellular space; and
vp—fractional volume of vascular space. The arterial input
function was derived from a population average in the
same tumor model as previously described [24]. Ktrans,
which is often a mixed measure of blood flow and vascular
permeability [25], was determined using in-house software
and expressed as median values of Ktrans in viable tumor
tissues. To assess Ktrans in the tumor periphery versus
tumor core, three-dimensional Ktrans voxel maps were
processed by binary erosion [26], which segmented the
Ktrans voxel distribution into three-dimensional concentric
shells that were each a single voxel thick. Using this seg-
mentation of voxels, Ktrans was averaged from the outer
one-third and inner two-thirds of tumor voxels to represent
the tumor periphery and the tumor core, respectively.
Magnetic resonance imaging is used extensively in the
clinic for high-resolution anatomical imaging [15, 27]. MR
anatomical images are based on detecting water molecules
under a magnetic field and the differences between water
molecules in different environments. In some cases, MRI is
also used to examine perfusion or blood flow in a tumor
using contrast agents and specialized imaging sequences
[27]. We have taken a similar approach in our study, and
imaged/quantified the effects of an injected contrast agent
as it appears and exits the tumor via the blood vessels. The
data are then processed to provide us with an estimate of
perfusion rates in the tissue before and after treatment. In
this way, we are able to associate the overall vascular
function of the tumor following Met-Gem and DC101
treatment.
Tumor levels of pro- and antiangiogenic factors
Harvested tumors from the three treatment groups at each
time point were snap-frozen in liquid nitrogen and
homogenized in a lysis buffer (50 mM HEPES, 10 %
glycerol, 1 % Triton X-100, 150 mM NaCl, 1 mM EDTA,
1.5 mM MgCl2, 100 mM NaF, 10 mM Na4P2O7, 100 lg/
ml PMSF, 5 lg/ml leupeptin, and 5 lg/ml aprotinin) using
a Polytron PT10-35 homogenizer (Kinematica AG,
Lucerne, Switzerland) and stored at -80 C. Total protein
concentration in each tumor lysate was determined using a
Micro BCA proteins assay kit (Pierce. Rockford, IL, USA).
The protein levels of human vascular endothelial growth
factor (hVEGF), mouse vascular endothelial growth factor
(mVEGF), mouse platelet-derived growth factor-BB
(mPDGF-BB), mouse stromal cell-derived factor-1a
(mSDF-1a), human placental growth factor (hPlGF), and
human thrombospondin-1 (hTSP-1) were determined using
ELISA kits (R&D Systems. Minneapolis, MN. USA).
Statistics
All results were presented as mean ± SE. Comparisons
were made with one-way analysis of variance followed by
the Newman–Keuls test, with P\ 0.05 as the criterion for
statistical significance.
Results
Metronomic gemcitabine is more effective
than DC101 in controlling tumor growth
and decreasing tumor metabolism
Metronomic gemcitabine (Met-Gem) treatment signifi-
cantly reduced the volume of PaCa8 and PaCa13 tumors
compared to the time-matched vehicle controls (93 and
87 %; P\ 0.01, respectively, Fig. 1a) by day 21. In con-
trast, no significant changes in tumor size were observed
with DC101 treatment, except in PaCa8 tumors on day 21
when the volumes were reduced by 32 % (P\ 0.01).
Throughout the course of treatment with DC101 or Met-
Gem, no significant changes in weight or adverse effects
were observed in the mice indicating that the treatments
were well tolerated.
Representative FDG-PET-CT images of PaCa13 tumor-
bearing mice on day 7 post-treatment initiation show that
tumor edges are well delineated by FDG uptake (Fig. 1b);
significant differences in tumor size among the three
groups (Veh-ctrl, DC101, and Met-Gem) are already
apparent at this time point. Mice treated with Met-Gem had
the smallest tumors of the three groups, and few necrotic
regions were present (areas with no FDG uptake) within
the tumor. In contrast, PET images of the Veh-ctrl and
DC101 tumors show the presence of a central necrotic core
with FDG uptake found predominantly in the proliferating
tumor edge.
The metabolic activity of tumors in the treatment groups
was also evaluated at all time points by measuring the
Angiogenesis (2016) 19:229–244 233
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uptake of FDG per unit volume of tumor tissue. The
average voxel intensity measurements, normalized to the
tumor volume, in each group of tumors are shown in
Fig. 1c. The voxel intensity is proportional to the amount
of FDG taken up by the cells in the tissue and is an indi-
cation of the tissue’s metabolic activity. The overall FDG-
PET data show that Met-Gem treatment decreased tumor
metabolism, whereas DC101 treatment actually increased
it. Compared to Veh-ctrl tumors, Met-Gem treatment sig-
nificantly reduced metabolic activity by *40 %
(P\ 0.05) in PaCa8 and PaCa13 tumors on day 7. With























































































































Fig. 1 Metronomic gemcitabine reduces the growth and metabolic
activity of pancreatic tumors. a Effects of treatments on the volume of
PaCa8 and PaCa13 tumors on days 3, 7, and 21 after initiation of
treatment. Symbols, mean of 6–11 tumors; bars, SE. *P\ 0.05,
**P\ 0.01, or ***P\ 0.005 versus vehicle control of corresponding
day; #P\ 0.01, versus DC101 of corresponding day. b Representative
FDG-PET-CT images of SCID mice bearing PaCa13 tumors in the
pancreas on day 7 after initiation of treatment. Tumor, white arrow;
bladder, white arrow heads. c Effects of treatments on FDG uptake in
PaCa8 and PaCa13 tumors at the three time points. Columns, mean of
2–6 tumors; bars, SE. *P\ 0.05; **P\ 0.01
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decreased metabolic activity for both pancreatic tumor
xenograft lines was seen following treatment with Met-
Gem. Treatment with DC101, however, did not change the
metabolic activity of the tumors (compared with controls)
on days 3 and 7; however, on day 21, the metabolic activity
increased significantly (P\ 0.05) by 44 and 23 % in
PaCa8 and PaCa13 tumors, respectively (Fig. 1c).
The percent necrotic tissue present in the tumors was
calculated, and the results show that by day 21 of treat-
ment, the Met-Gem groups (PaCa8 and PaCa13 tumors)
were significantly less necrotic than the Veh-ctrl group
(P\ 0.01; Fig. 2). In contrast, DC101 treatment only
reduced necrosis in PaCa8 tumors on day 3, and the extent
of necrosis at all other time points was similar between
DC101-treated and Veh-ctrl tumors. Excised tumors were
also analyzed for cell proliferation (Ki67) and death
(TUNEL) with immunofluorescence staining. Quantifica-
tion of Ki67 and TUNEL staining (Fig. 2) revealed that
levels of Ki67? and TUNEL staining in tumors from the
Met-Gem treatment groups decreased over time in PaCa8
and Pac13 tumors compared to Veh-ctrl. The extent of
Ki67 and TUNEL staining in DC101-treated tumors were
generally the same as Veh-ctrl tumors except in PaCa8
tumors on day 3 when levels of Ki67 were significantly
lowered.
Tumors treated with metronomic gemcitabine have
a higher density of blood vessels that are more
functional
Representative composite images of PaCa13 tumor sec-
tions from each treatment group (day 7) are shown in Fig. 3
(See Additional File 1 for PaCa8 images). The images
clearly show that fewer necrotic regions (areas outlined in
yellow) are present in tumors treated with Met-Gem as
indicated by the previously (Fig. 2) and that the vessels
(red) are more evenly distributed throughout the tumor than
in Veh-ctrl- and DC101-treated tumors. Selected vascular
parameters for the stained images were quantified and are










































































































































less necrotic and have lower
levels of proliferation and
apoptosis compared to DC101-
treated tumors.
Immunofluorescence staining of
tumor sections was quantified
for necrosis, proliferation
(Ki67? staining), and apoptosis
(TUNEL? staining). Columns,
mean of 6–8 tumors; bars, SE.
*P\ 0.05; **P\ 0.01;
***P\ 0.005. aP\ 0.05,
bP\ 0.01, or cP\ 0.001,
versus day 3 of corresponding
treatment group. dP\ 0.05 or
eP\ 0.01, versus day 7 of
corresponding treatment group
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tumors from each treatment group was determined by
averaging the distance between tissue pixels to the nearest
CD31? pixel, where shorter distances indicate higher
vessel density. With the exception of PaCa8 tumor (day 3),
all DC101-treated tumors had significantly (P\ 0.01)
lower vessel density than Veh-ctrls and the vessel density
decreased even more with time. Only PaCa13 tumors
treated with Met-Gem had a significantly higher density of
blood vessels (P\ 0.005) on days 7 and 21 when com-
pared to Veh-ctrl tumors. Overall, vascular density in the
metronomic gemcitabine-treated tumors were significantly
(P\ 0.005) greater than the DC101-treated tumors
(Figs. 3, 4).
The levels of double positive CD31 and Hoechst pixels
in the tumor were quantified to evaluate the number of
blood vessels that contained Hoechst as an indicator of
vessel function at the time of injection. This analysis
revealed that, compared to the Veh-ctrl tumors, signifi-
cantly more blood vessels in Met-Gem-treated tumors were
carrying the dye except for PaCa13 on day 21 (Fig. 4;
P\ 0.05). By day 7 of Met-Gem treatment, the number of
vessels positive for Hoechst staining for PaCa8 and PaCa13
tumors had increased by *twofold compared to Veh-ctrl
tumors. On days 3 and 7 after initiation of treatment,
DC101-treated PaCa13 tumors also contained significantly
(P\ 0.05) more Hoechst than their Veh-ctrl counterparts.
This was not the case for DC101-treated PaCa8 tumors,
however, and the number of Hoechst positive blood vessels
was similar to controls.
The levels of hypoxia in PaCa8 and PaCa13 were also
evaluated using the exogenous hypoxia marker, EF5 [28,
29]. The drastic decrease in hypoxia is seen visually by the
lack of EF5 adducts present in the cells (Fig. 3, green stain)
of Met-Gem-treated tumors. Quantification of the EF5
positive pixels in the tumors (Fig. 4) shows that the number
of hypoxic cells present is reduced, and significantly so by
day 7 (PaCa8 and PaCa13) and 21 (PaCa8). Tumor hypoxia
in DC101-treated tumors was similar to that in Veh-ctrl
tumors, and in fact a significant (P\ 0.05) increase in
hypoxia was seen in PaCa8 tumors on day 7. Overall,
quantification of hypoxic cells in the sections indicates that
Met-Gem treatment decreased hypoxia while DC101
treatment had no effect or increased hypoxia in the tumors
(Fig. 4).
Metronomic gemcitabine-treated tumors are better
perfused than DC101-treated tumors
Representative Ktrans maps of PaCa13 tumors, 7 days after
initiation of treatment, are shown in Fig. 5a. The presence
of the contrast agent (Gd-DTPA) in the tumor is indicated






Fig. 3 Metronomic gemcitabine-treated tumors are better perfused,
have higher intratumoral microvessel density, and lower levels of
hypoxia than DC101-treated tumors. Representative composite
images of PaCa13 tumor sections on day 7 of treatment with vehicle
(Veh-Ctrl; 0.9 % saline), DC101 (800 lg, q3d), or metronomic
gemcitabine (Met-Gem; 30 mg/kg, q3d). The presence of Hoechst
33362 (blue) indicates tissue perfusion. Intratumoral microvessels and
hypoxia are detected by CD31 (red) and EF5 (green) immunofluo-
rescence staining, respectively. Necrotic regions (pale green) are
outlined in yellow
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high concentrations of Gd-DTPA, respectively. The pres-
ence of Gd-DTPA indicates areas of tissue that are actively
perfused at the time of the scan, and its concentration a
measure of relative perfusion rates. The highest levels of
perfusion in tumors from the Veh-ctrl and DC101 groups
were found in the periphery (green–blue areas), while the
center of these tumors either had no (gray unmapped areas)
or low perfusion (red areas). In tumors treated with Met-
Gem, however, not only were higher levels of the contrast
agent (blue-green) found, but the contrast agent was more
uniformly distributed throughout the tumor. The median
Ktrans values of the outer, one-third periphery of the tumor
and those of the inner, two-third core of the tumor, 7 days
after initiation of treatment median are shown in Fig. 5b,
and quantitatively confirm the difference in perfusion rates
observed in the color maps. Median Ktrans levels in the
periphery of Veh-ctrl- and DC101-treated tumors (PaCa8
and PaCa13) are higher than in the core, where they are
almost negligible. In contrast, median Ktrans values in Met-
Gem-treated tumors were higher in the tumor core than in
their periphery. In general too, the overall Ktrans values in
Met-Gem-treated tumors were higher than those found in
Veh-ctrl and DC101-treated tumors indicating that Met-
Gem treatment improves the overall perfusion in the tumor.
The average of median Ktrans values derived from the
entire MRI-pixel map of the tumor on days 3, 7, and 21 is
shown in Fig. 5c. Median Ktrans values for DC101-treated
tumors and Veh-ctrl tumors were similar at all time points in
both PaCa8 and PaCa13. In contrast, tumors treated with
Met-Gem for 7 days had significantly (P\ 0.01) higher
Ktrans values than those treated with Veh-ctrl or DC101
(*twofold and *fivefold, respectively, for PaCa8 and
PaCa13 tumors compared to their corresponding controls).
Interestingly, after 21 days of Met-Gem treatment, the
median Ktrans values dropped significantly (P\ 0.05) com-
pared to day 7 values. The data graphed in Fig. 5c show that
Met-Gem treatment improves tumor perfusion transiently,
whereas DC101 had little or no effect on the tumors.
Metronomic gemcitabine decreases the levels of pro-
and anti-angiogenic factors
The levels of pro- and antiangiogenic factors as detected by































































































































































































perfusion, and tumor hypoxia
in tumors treated with saline,
DC101, and Met-Gem.
Immunofluorescence staining
of tumor sections was
quantified for intratumoral
microvessel density (average




and percent hypoxic areas
(EF5? staining). Columns,
mean of 2–9 tumors; bars, SE.
*P\ 0.05; **P\ 0.01;
***P\ 0.005. aP\ 0.05,
bP\ 0.01, or cP\ 0.005,
versus day 3 of corresponding
treatment group. dP\ 0.05 or
eP\ 0.01, versus day 7 of
corresponding treatment group
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PaCa8 and PaCa13 tumors on day 7 and 21 following
initiation of treatment, Met-Gem significantly (P\ 0.05)
decreased the levels of the proangiogenic factors hVEGF
and mVEGF. On the other hand, DC101 increased the
levels of hVEGF and mVEGF, but this could be attributed
to the fact that DC101 is an antibody against VEGFR-2,
which would increase levels of free VEGF. The other
proangiogenic factor, mPDGF-BB, was also significantly
(P\ 0.05) decreased over time with Met-Gem treatment in
PaCa8 tumors. Met-Gem and DC101 did not significantly
alter the levels of hPlG, mSDF-a, and hTSP-1 (see Addi-
tional File 2).
Discussion
The aim of this study was to better understand the anti-
tumor effects of metronomic gemcitabine (Met-Gem) in










































































































Fig. 5 Metronomic gemcitabine improves tumor perfusion in pri-
mary pancreatic tumors. a Representative Ktrans maps of PaCa13
tumors on day 7 of treatment are superimposed on the corresponding
axial anatomical MR images. Higher Ktrans values indicate better
perfusion. b Comparison of median Ktrans values between the outer
one-third (periphery) and inner two-thirds (core) of PaCa8 and
PaCa13 tumors on day 7 after initiation of treatment. Lines, mean of
3–4 tumors. c Effects of treatments on median Ktrans values at the
three time points. Columns, mean of 3–4 tumors; bars, SE.
*P\ 0.05; **P\ 0.01; ***P\ 0.005. bP\ 0.01, versus day 3 of
corresponding treatment group; dP\ 0.05 or eP\ 0.01, versus day 7
of corresponding treatment group
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show that Met-Gem is very effective at controlling pan-
creatic tumor growth, with the average volume of Met-
Gem-treated tumors almost 10 times smaller than that of
Veh-ctrl tumors (Fig. 1a). The avidity of Met-Gem-treated
tumors for FDG, a radiolabelled glucose analog, was
measured with PET to evaluate the tumors’ glucose
requirements and metabolic activity as a surrogate marker
for in situ cell viability and proliferation. The PET data
show that FDG is distributed homogenously in Met-Gem-
treated tumors, which have few necrotic areas, but that the
tumors were significantly less avid for FDG compared to
Veh-ctrl tumors. Interestingly, FDG uptake in tumors
treated with Met-Gem was lower as soon as day 3, whereas
tumor volume data gave no indication of any response to
metronomic treatment at this early time point (Fig. 1a, c).
The levels of Ki67 and TUNEL staining in frozen sections
from the Met-Gem-treated tumors (Fig. 2) were also lower
than those in the Veh-ctrl tumors, consistent with the FDG
data (Fig. 1). Met-Gem treatment, therefore, appears to
exert a cytostatic effect on the tumor wherein the cancer
cells are still alive, but not actively proliferating.
Metronomic dosing with other drugs has been reported
to decrease tumor perfusion [3, 5, 30, 31], thus treatment
induced changes and function in the tumors’ vasculature
were examined using immunohistochemistry and DCE-
MRI. The density and functionality of the tumor vascula-
ture in our study were quantified, and the data (Fig. 4)
indicate that Met-Gem treatment increases vascular density
and improved function compared to Veh-ctrl tumors.
Hypoxic cells were virtually absent in Met-Gem-treated
tumors (Figs. 3, 4) and this is likely due to a more func-
tional vascular system which delivers more oxygen and
lower metabolic rates. Similar findings have also been
reported in a breast cancer model treated with orally
administered, low-dose gemcitabine [11].
The Ktrans data (Fig. 5) indicate blood flow is homoge-
nous throughout the tissue following Met-Gem treatment.
Moreover, the average Ktrans values increase by day 7
compared to Veh-ctrl tumors even though the average
tumor volume in all groups are similar. The Ktrans values,
however, decrease by day 21, suggesting that the changes































































































































































Fig. 6 The effects of Met-
Gem and DC101 on pro- and
antiangiogenic factors.
Metronomic gemcitabine
decreases the levels of human
and mouse vascular endothelial
growth factor (hVEGF and
mVEGF, respectively), and
mouse platelet-derived growth
factor (mPDGF-BB) in tumors.
Tumor-bearing SCID mice
were treated with the vehicle
(Veh-Ctrl; 0.9 % saline),
DC101 (800 lg, q3d), or
metronomic gemcitabine (Met-
Gem; 30 mg/kg, q3d) and were
euthanized on days 3, 7, and 21
following initiation of
treatment. Effects of treatments
on hVEGF, mVEGF, and
mPDGF-BB were measured
with ELISAs. Symbols, means
of 3–9 tumors; bars, SE.
*P\ 0.05, versus the vehicle
control group at the same time
point. #P\ 0.05, versus the
DC101-treated group at the
same time point
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initial increase in perfusion observed is transient. Other
studies report that treatment with Met-Gem decreases
tumor perfusion [30], but this may be a reflection of when
the scans were carried out with respect to the treatment as
few longitudinal studies such as ours have been carried out.
Since Met-Gem treatment had such dramatic effects on
the density and function of tumor vessels, we treated the
same tumor models with DC101 to examine the effects of a
dedicated antiangiogenic agent on tumor growth, metabo-
lism, and vascular function. DC101, the murine analog of
ramucirumab [32], was used because the vasculature that
develops in the orthotopic tumors is of murine origin.
DC101 therefore only targets actively growing tumor
vasculature and has no effect on the human cancer cells.
Our results indicate that DC101 treatment is much less
effective than Met-Gem. Treatment with DC101 only
reduced the volume of PaCa13 tumors by about 3 times
after 21 days compared to Veh-ctrl tumors. The uptake and
distribution of FDG in Veh-ctrl- and DC101-treated tumors
were also similar—uptake was concentrated at the
periphery, and the tumors had large central necrotic areas
with no uptake. Moreover, the avidity of the DC101-treated
and Veh-ctrl tumors for FDG was higher than that in Met-
Gem-treated tumors indicating that the DC101-treated
tumors, albeit highly necrotic, were still actively prolifer-
ating at the periphery, a pattern typical of rapidly growing
tumors (Fig. 1). Similarly, levels of cell proliferation and
apoptosis (Ki67 and TUNEL, respectively; Fig. 2) in
DC101-treated tumors were similar to those present in
Veh-ctrl tumors. Our data further show that DC101 was
toxic to the vasculature (Fig. 4), but the consequences were
not detrimental to tumor growth at least in these models
and time points. As expected, DC101 reduced vascular
density in the primary pancreatic tumor xenografts in our
study as reported previously [13]; the same group also
reported that DC101 reduced tumor volume [13], whereas
no significant effects on tumor volume were seen in our
study. Unfortunately, it is not possible to draw any definite
conclusions between the two studies as our group used
primary orthotopic human tumor xenografts [9], which
bears the histology of the original resected patient tumor,
whereas the other group used tumors derived from cell
lines which tend to contain homogeneous sheets of cancer
cells and a well distributed vascular system.
DC101 treatment did not change in situ tumor perfusion
as evaluated with DCE-MRI over time either, and in fact,
the median Ktrans values in tumors treated with DC101
were similar to those in Veh-ctrl tumors. Perfusion in Veh-
ctrl- or DC101-treated tumors was also limited to the
periphery of the tumor (Figs. 5a, b). The aggregate data for
DC101 treatment indicate that specifically targeting tumor
vasculature (via VEGFR-2) in these primary pancreatic
tumors has a minor effect in one tumor line, but that in
general, the tumors in both groups behaved like Veh-ctrl
tumors and continued expanding outwards from a central
necrotic core.
Since Met-Gem and DC101 affected the tumor vascu-
lature, and vascular growth and remodeling is a delicate
balance of pro- and anti-angiogenic factors [33], selected
molecular factors implicated in vascular reorganization
were assayed (Additional File 2). Met-Gem reduced the
levels of proangiogenic factors VEGF and PDGF-BB
compared to Veh-ctrls, suggesting that the treatment has
some antiangiogenic effect. VEGF is known to control
endothelial cell growth, migration, and survival, but over-
expression of VEGF typically causes abnormal, random,
and disorganized vasculature [34, 35]. Since the levels of
VEGF decreased with Met-Gem treatment, the tumor
vasculature would be expected to become less haphazard
and disorganized as seen here. The results reported here
would appear consistent with the hypothesis originally put
forth by Jain et al. [35] that metronomic therapy may
induce vascular normalization. DC101 treatment increased
the levels of both mouse and human VEGF, indicating that
VEGFR-2 was successfully blocked, but somewhat sur-
prisingly did not change vasculature patterns. Tumors are
known to become resistant to antiangiogenic treatment by
using alternative pathways to compensate for the inhibition
of VEGFR-2 [36]. However, in this case, no change in
PlGF, PDGF-BB, and SDF-1a was seen over the 3-week
treatment period. It appears that the primary pancreatic
tumors used in our study can survive VEGFR-2 inhibition
without activating other pathways.
The differences in response to DC101 (a targeted drug)
and Met-Gem (low-dose cytotoxic) provide some insight
into how each affects tumor growth. The observations from
tumors treated with Met-Gem are somewhat paradoxical
since the tumors appear ‘healthier’—they had more func-
tional blood vessels, less necrosis, and virtually no
hypoxia—and yet the tumors did not proliferate, or at least
proliferated slowly compared to Veh-ctrl- or DC101-trea-
ted tumors. Gemcitabine would initially cull proliferating
endothelial and cancer cells to leave behind a tumor with
mature blood vessels that are more functional and fewer
cancer cells. The continuous delivery of gemcitabine sub-
sequently appears to dampen the proliferative capacity of
the cells. Since the drug is present more often during
metronomic therapy, the cancer cells and endothelial cells
may have no chance to recover as they do during
chemotherapy breaks in conventional MTD therapy. The
result is a tumor in stasis where cells are still viable, but
less proliferative than normal. In contrast, targeting
VEGFR-2 with DC101 in these primary tumors may not be
effective because the VEGF pathway is not an important
therapeutic target in pancreatic cancer [37], or because
alternative pathways may be utilized. Similar results have
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123
also been reported in the clinic where targeted anti-VEGF
treatment in pancreatic cancer was not successful, and
failure of DC101 to Veh-ctrl tumors in our study mirrors
these findings where inhibition of a single target was
insufficient to achieve tumor control [38].
At present, the consequences of long-term Met-Gem
treatment are unknown. The tumor may eventually be
eradicated, or it could become refractory to Met-Gem and
re-grow. However, it is tantalizing to speculate that if the
treatment holds tumor growth in check indefinitely, Met-
Gem treatment could be used as an additional therapeutic
option where the goal is to attain a cytostatic state rather
than to reduce tumor volume at all costs. Several intriguing
implications arise from the effects of Met-Gem. Using non-
invasive imaging technologies, as in our multi-modality
study, may also be useful in determining therapeutic
opportunities that arise from Met-Gem treatment. The
homogenous perfusion due to improvements in vascular
function may provide better access for a second drug to all
cancer cells as was previously shown by our group [17] and
could potentiate its cell-killing effects. DCE-MRI could be
used to determine how sequential drug treatments could be
used. The classic end point for drug activity is reduction of
tumor volume [39]. However, new therapies that induce a
cytostatic state [40] require other end points for the
assessment of response and efficacy [41]. FDG-PET may
be useful as a complementary measure of drug activity
[42–44] because the technique is non-invasive, applicable
to multiple scans, and measures a tumor’s metabolic
activity which may change before tumor volumes are
affected [45, 46]. This is exemplified by the FDG-PET
scans in our study which show decreased cell viability
before changes in tumor volume are observed after 3 days
of treatment. There has only been a handful of studies of
FDG-PET response with metronomic treatment of other
drugs and other cancer models [47, 48], and its utility as an
early surrogate response marker remains promising. We are
the first to study FDG uptake with metronomic gemcitabine
in pancreatic cancer and further studies will be required to
confirm the predictive benefits of FDG-PET in this setting.
We have previously shown that Met-Gem has better
efficacy at lower doses than conventional maximum tol-
erated doses [9]. In this study, we further confirmed that
Met-Gem treatment is cytostatic and improves vasculature
function transiently and that changes in the tumors’ via-
bility can be detected before changes in their volume.
DC101 treatment indicated that a treatment specific for
VEGFR-2 may be less effective if the targeted pathway is
no longer important in disease progression or if other
pathways can compensate for its activity. However, a
therapeutic strategy such as Met-Gem which provides the
continuous presence of low-dose gemcitabine may control
not only the proliferation of endothelial cells, but also
cancer cells in a two-pronged attack. This approach appears
to control cell growth well, as evidenced by the FDG-PET
and Ki67 data, precisely because it is not targeted to a
specific component of the disease.
There is clinical interest in combining metronomic
therapies with dedicated anti-angiogenic agents as a ther-
apeutic strategy for cancer treatments [49–53]. The thera-
peutic effects of combinations such as DC101 and
metronomic vinblastine in neuroblastoma [8], DC101 with
metronomic cisplatin or doxorubicin in breast cancer [54],
and bevacizumab with metronomic irinotecan in colorectal
cancer [55] have been examined in preclinical models.
Phase I/II clinical studies have also been carried out in
glioblastoma with bevacizumab and metronomic irinotecan
[56, 57] and breast cancer with bevacizumab and metro-
nomic cyclophosphamide [58]. The studies showed that the
combination treatments are well tolerated, and in some
cases produced stable disease. However, few conclusions
can be made about the mechanisms of the combination
therapies due to variation in study methods and small
population patients. The consensus at the moment is that a
better understanding of how metronomic therapies interact
with anti-angiogenic therapies is needed and that more
predictive biomarkers and imaging techniques are required
to facilitate the sequencing (or monitoring effects) of the
two treatments [49]. In our study, the data indicate that
Met-Gem causes a transient period of improved perfusion
and low hypoxia which could be advantageous for the
delivery of a second drug, or radiation therapy, respec-
tively. Met-Gem and DC101 were not combined in this
study and so we are unable to comment on any potential
synergies between the two treatments. However, our study
also shows the utility of imaging technologies to assess
changes in the physiology of the tumor to guide changes in
initial treatment to take advantage of transient treatment
opportunities in a combination or sequential setting.
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